Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Breezmist
- Development stage
- Unknown
- Lead developer
- Alde Medi Impex
- Modality
- Small Molecules
- Administration
- Intranasal
01
Overview
Breezmist is a sodium chloride nasal spray (20 ml) developed and marketed by Alde Medi Impex under its Somediza H Life Sciences division. Formulated as a saline solution, Breezmist is designed to provide relief from nasal dryness, irritation, and congestion. It works by moisturizing the nasal mucosa, softening thick or crusty mucus, and facilitating its clearance from the nasal passages. This non-medicated, small molecule therapy is commonly used as a supportive treatment for nasal congestion associated with the common cold, sinusitis, allergies, or dry environmental conditions.
- Brand names
- Breezmist
- Other names
- Sodium chloride nasal spraySodium chloride nasal spray 20 mL
Beyond the preview
Go deeper on Breezmist.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Breezmist.